4528:TYO
Ono Pharmaceutical Co Ltd
2.419,00 JPY
arrow_upward
+1,62%(+38,50) 1 zi
10 aug., 15:30:00 GMT+9 · JPY
search
Toate simbolurile
1 zi
5 zile
1 lună
6 luni
Anul curent până azi
1 an
5 ani
MAX
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru 4528...
Deschide
2.378 JPY
Mare
2.423 JPY
Mic
2.359 JPY
Capitalizarea bursieră
1,21 tril.
Volum mediu
1,58 mil.
Volum
1,34 mil.
Dividende
3,31 %
Dividende trimestriale
20 JPY
Data ex-dividend
29 sept. 2026
Raportul P/V
14,91
Prețul ridicat pe 52 de săptămâni
2.674 JPY
Prețul redus pe 52 de săptămâni
1.596 JPY
Rezultatul pe acțiune
162 JPY
Acțiuni aflate în circulație
514,12 mil.
Nr. de angajați
4 K
Deschide
2.378 JPY
Mare
2.423 JPY
Mic
2.359 JPY
Capitalizarea bursieră
1,21 tril.
Volum mediu
1,58 mil.
Volum
1,34 mil.
Dividende
3,31 %
Dividende trimestriale
20 JPY
Data ex-dividend
29 sept. 2026
Raportul P/V
14,91
Prețul ridicat pe 52 de săptămâni
2.674 JPY
Prețul redus pe 52 de săptămâni
1.596 JPY
Rezultatul pe acțiune
162 JPY
Acțiuni aflate în circulație
514,12 mil.
Nr. de angajați
4 K
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Despre Ono Pharmaceutical Co Ltd
Director executivGyo Sagara | Gyo Sagara
Angajați4,21 K
Înființată la1717
SediuOsaka, Prefectura Osaka, Japonia
Domeniu-
Siteono-pharma.com
Conținutul generat de AI poate include greșeli. Află mai multe